RC48 for Neoadjuvant Chemotherapy of HER2 Positive Breast Cancer
NCT05134519
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Breast Cancer
HER2-positive Breast Cancer
Interventions
DRUG:
Recombinant humanized anti-HER2 monoclonal antibody-MMAE coupling agent (RC48-ADC)
Sponsor
Xijing Hospital